Bristol Myers adds to neoadjuvant win for Opdivo in lung cancer, escalating early cancer showdown with Merck
Bristol Myers Squibb and Merck are locked in a heated race to bring their blockbuster PD-(L)1 drugs into early cancer patients as part of potentially curative combinations. The approvals have been coming fast and heavy, and Bristol Myers keeps adding to its case for a big-time FDA nod in lung cancer.
A combination of Opdivo and chemo in the neoadjuvant setting before surgery cut the risk of recurrence or death in patients with stage IB to IIIA non-small cell lung cancer over pre-surgery chemo alone, acing the second primary endpoint in the Phase III CHECKMATE-816 study, Bristol Myers said Monday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.